Literature DB >> 29328389

miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.

Qingwei Wu1, Yingying Zhao1, Yiyuan Sun1, Xiaojun Yan1, Peihua Wang1.   

Abstract

Upregulation of programmed death 1 ligand 1 (PD-L1) in cancer cells and its ligation to PD-1 on T cells facilitates cancer cell escape from immune surveillance. Therapies with PD-1 or PD-L1 antibodies have resulted in marked clinical responses in various cancer types. Hence, modulators that inhibit PD-L1 expression in cancer cells may serve as a novel strategy by which to enhance host immune responses. In the present study, we investigated the effects of miR-375 on PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells by qRT-PCR and western blot analyses. We confirmed that miR-375 inhibited IFN-γ-induced PD-L1 surface expression in HNSCC cells, and we observed that Janus kinase 2 (JAK2) is a bona fide target of miR-375 and further activated signal transducer and activator of transcription 1 (STAT1). Additionally, miR-375-mediated inhibition of PD-L1 expression was dependent on the JAK2/STAT1 pathway. Therefore, by attenuating PD-1/PD-L1 signaling, miR-375 may also serve as a modulator to increase the cell immune responses to HNSCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29328389     DOI: 10.3892/or.2018.6177

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

Review 1.  Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance.

Authors:  Shuya Liu; Saber Imani; Youcai Deng; Janak L Pathak; Qinglian Wen; Yue Chen; Jingbo Wu
Journal:  Onco Targets Ther       Date:  2020-06-24       Impact factor: 4.147

Review 2.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 3.  Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.

Authors:  Alexandre Perrier; Audrey Didelot; Pierre Laurent-Puig; Hélène Blons; Simon Garinet
Journal:  Biomolecules       Date:  2020-07-16

Review 4.  MicroRNA-375: potential cancer suppressor and therapeutic drug.

Authors:  Jiahui Wei; Yiran Lu; Ruiqing Wang; Xiangzhu Xu; Qing Liu; Song He; Huihao Pan; Xinmiao Liu; Bao Yuan; Yu Ding; Jiabao Zhang
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

5.  Analysis of miR-375-3p, miR-197-3p, and miR-15a-5p Expression and Their Clinical Relevance as Biomarkers in Lung Cancer.

Authors:  Sachin Kumar; Jyoutishman Saikia; Surender K Sharawat; Prabhat S Malik; Sunil Kumar; Anant Mohan
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins.

Authors:  Soudeh Ghafouri-Fard; Bashdar Mahmud Hussen; Mahdi Mohaqiq; Hamed Shoorei; Aria Baniahmad; Mohammad Taheri; Elena Jamali
Journal:  Front Oncol       Date:  2022-03-23       Impact factor: 6.244

Review 7.  The role of cancer-derived microRNAs in cancer immune escape.

Authors:  Ming Yi; Linping Xu; Ying Jiao; Suxia Luo; Anping Li; Kongming Wu
Journal:  J Hematol Oncol       Date:  2020-03-28       Impact factor: 17.388

Review 8.  Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.

Authors:  Elena Shklovskaya; Helen Rizos
Journal:  Int J Mol Sci       Date:  2020-09-27       Impact factor: 5.923

Review 9.  Immune Aging and How It Works for Inflammation and Fibrosis.

Authors:  Hiroshi Nishiura; Mai Imasaka; Koji Yamanegi; Jiro Fujimoto; Masaki Ohmuraya
Journal:  Front Physiol       Date:  2022-01-04       Impact factor: 4.566

Review 10.  MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies.

Authors:  Mahrou Vahabi; Giovanni Blandino; Silvia Di Agostino
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.